Cargando…

The relation between body fat distribution, plasma concentrations of adipokines and the metabolic syndrome in patients with clinically manifest vascular disease

INTRODUCTION: We evaluated the relationship between adipokine plasma concentrations and body fat distribution and the metabolic syndrome. METHODS: In a cohort of 1215 patients with clinically manifest vascular disease the relation between subcutaneous adipose tissue, visceral adipose tissue, waist c...

Descripción completa

Detalles Bibliográficos
Autores principales: Schrover, Ilse M, van der Graaf, Yolanda, Spiering, Wilko, Visseren, Frank LJ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146311/
https://www.ncbi.nlm.nih.gov/pubmed/30052066
http://dx.doi.org/10.1177/2047487318790722
_version_ 1783356377477939200
author Schrover, Ilse M
van der Graaf, Yolanda
Spiering, Wilko
Visseren, Frank LJ
author_facet Schrover, Ilse M
van der Graaf, Yolanda
Spiering, Wilko
Visseren, Frank LJ
author_sort Schrover, Ilse M
collection PubMed
description INTRODUCTION: We evaluated the relationship between adipokine plasma concentrations and body fat distribution and the metabolic syndrome. METHODS: In a cohort of 1215 patients with clinically manifest vascular disease the relation between subcutaneous adipose tissue, visceral adipose tissue, waist circumference, body mass index and plasma concentrations of adipsin, chemerin, monocyte chemoattractant protein-1, migration inhibitory factor, nerve growth factor, resistin, plasma amyloid A1, adiponectin, leptin, plasminogen activator inhibitor-1 and hepatic growth factor were cross-sectionally assessed with linear regression and adjusted for age and gender. The relation between adipokines and the metabolic syndrome was cross-sectionally evaluated using logistic regression. An adipokine profile was developed to measure the effect of combined rather than single adipokines. RESULTS: Adiposity was related to higher nerve growth factor, hepatic growth factor, migration inhibitory factor, leptin and adipsin and with lower chemerin, plasminogen activator inhibitor-1, resistin, plasma amyloid A1 and adiponectin. The strongest positive relations were between body mass index and adipsin (β 0.247; 95% CI 0.137–0.356) and leptin (β 0.266; 95% CI 0.207–0.324); the strongest negative relations were between body mass index and plasma amyloid A1 (β –0.266; 95% CI –0.386 to –0.146) and visceral adipose tissue and adiponectin (β –0.168; 95% CI –0.226 to –0.111). There was no relation between subcutaneous adipose tissue and adipokines. Odds for the metabolic syndrome were higher with each 1 SD higher hepatic growth factor (OR 1.21; 95% CI 1.06–1.38) and leptin (OR 1.26; 95% CI 1.10–1.45) and lower with each 1 SD higher adiponectin (OR 0.73; 95% CI 0.64–0.83) and resistin (OR 0.85; 95% CI 0.74–0.97). The adipokine profile was related to the metabolic syndrome (OR 1.03; 95% CI 1.00–1.06). CONCLUSION: Plasma concentrations of adipokines are related to obesity and body fat distribution. The relation between adipokine concentrations and the metabolic syndrome is independent of visceral adipose tissue.
format Online
Article
Text
id pubmed-6146311
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-61463112018-09-28 The relation between body fat distribution, plasma concentrations of adipokines and the metabolic syndrome in patients with clinically manifest vascular disease Schrover, Ilse M van der Graaf, Yolanda Spiering, Wilko Visseren, Frank LJ Eur J Prev Cardiol Obesity INTRODUCTION: We evaluated the relationship between adipokine plasma concentrations and body fat distribution and the metabolic syndrome. METHODS: In a cohort of 1215 patients with clinically manifest vascular disease the relation between subcutaneous adipose tissue, visceral adipose tissue, waist circumference, body mass index and plasma concentrations of adipsin, chemerin, monocyte chemoattractant protein-1, migration inhibitory factor, nerve growth factor, resistin, plasma amyloid A1, adiponectin, leptin, plasminogen activator inhibitor-1 and hepatic growth factor were cross-sectionally assessed with linear regression and adjusted for age and gender. The relation between adipokines and the metabolic syndrome was cross-sectionally evaluated using logistic regression. An adipokine profile was developed to measure the effect of combined rather than single adipokines. RESULTS: Adiposity was related to higher nerve growth factor, hepatic growth factor, migration inhibitory factor, leptin and adipsin and with lower chemerin, plasminogen activator inhibitor-1, resistin, plasma amyloid A1 and adiponectin. The strongest positive relations were between body mass index and adipsin (β 0.247; 95% CI 0.137–0.356) and leptin (β 0.266; 95% CI 0.207–0.324); the strongest negative relations were between body mass index and plasma amyloid A1 (β –0.266; 95% CI –0.386 to –0.146) and visceral adipose tissue and adiponectin (β –0.168; 95% CI –0.226 to –0.111). There was no relation between subcutaneous adipose tissue and adipokines. Odds for the metabolic syndrome were higher with each 1 SD higher hepatic growth factor (OR 1.21; 95% CI 1.06–1.38) and leptin (OR 1.26; 95% CI 1.10–1.45) and lower with each 1 SD higher adiponectin (OR 0.73; 95% CI 0.64–0.83) and resistin (OR 0.85; 95% CI 0.74–0.97). The adipokine profile was related to the metabolic syndrome (OR 1.03; 95% CI 1.00–1.06). CONCLUSION: Plasma concentrations of adipokines are related to obesity and body fat distribution. The relation between adipokine concentrations and the metabolic syndrome is independent of visceral adipose tissue. SAGE Publications 2018-07-27 2018-09 /pmc/articles/PMC6146311/ /pubmed/30052066 http://dx.doi.org/10.1177/2047487318790722 Text en © The European Society of Cardiology 2018 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Obesity
Schrover, Ilse M
van der Graaf, Yolanda
Spiering, Wilko
Visseren, Frank LJ
The relation between body fat distribution, plasma concentrations of adipokines and the metabolic syndrome in patients with clinically manifest vascular disease
title The relation between body fat distribution, plasma concentrations of adipokines and the metabolic syndrome in patients with clinically manifest vascular disease
title_full The relation between body fat distribution, plasma concentrations of adipokines and the metabolic syndrome in patients with clinically manifest vascular disease
title_fullStr The relation between body fat distribution, plasma concentrations of adipokines and the metabolic syndrome in patients with clinically manifest vascular disease
title_full_unstemmed The relation between body fat distribution, plasma concentrations of adipokines and the metabolic syndrome in patients with clinically manifest vascular disease
title_short The relation between body fat distribution, plasma concentrations of adipokines and the metabolic syndrome in patients with clinically manifest vascular disease
title_sort relation between body fat distribution, plasma concentrations of adipokines and the metabolic syndrome in patients with clinically manifest vascular disease
topic Obesity
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146311/
https://www.ncbi.nlm.nih.gov/pubmed/30052066
http://dx.doi.org/10.1177/2047487318790722
work_keys_str_mv AT schroverilsem therelationbetweenbodyfatdistributionplasmaconcentrationsofadipokinesandthemetabolicsyndromeinpatientswithclinicallymanifestvasculardisease
AT vandergraafyolanda therelationbetweenbodyfatdistributionplasmaconcentrationsofadipokinesandthemetabolicsyndromeinpatientswithclinicallymanifestvasculardisease
AT spieringwilko therelationbetweenbodyfatdistributionplasmaconcentrationsofadipokinesandthemetabolicsyndromeinpatientswithclinicallymanifestvasculardisease
AT visserenfranklj therelationbetweenbodyfatdistributionplasmaconcentrationsofadipokinesandthemetabolicsyndromeinpatientswithclinicallymanifestvasculardisease
AT schroverilsem relationbetweenbodyfatdistributionplasmaconcentrationsofadipokinesandthemetabolicsyndromeinpatientswithclinicallymanifestvasculardisease
AT vandergraafyolanda relationbetweenbodyfatdistributionplasmaconcentrationsofadipokinesandthemetabolicsyndromeinpatientswithclinicallymanifestvasculardisease
AT spieringwilko relationbetweenbodyfatdistributionplasmaconcentrationsofadipokinesandthemetabolicsyndromeinpatientswithclinicallymanifestvasculardisease
AT visserenfranklj relationbetweenbodyfatdistributionplasmaconcentrationsofadipokinesandthemetabolicsyndromeinpatientswithclinicallymanifestvasculardisease